Diatech Pharmacogenetics

Diatech Pharmacogenetics is a leading Italian Precision Medicine company that specializes in the development, production, and sales of pharmacogenetics tests for cancer precision medicine. The company provides molecular diagnostic tools for precision medicine, offering end-to-end solutions for complex molecular diagnostic procedures. With over 10 years of experience, Diatech has successfully implemented various nucleic acid analysis technologies into regulated diagnostic pipelines, including pyrosequencing, mass spectrometry, and digital molecular barcoding.

Based in Italy, the company serves as a key partner for leading cancer centers in Italy and abroad. Diatech's CE-IVD solutions enable the extraction and analysis of nucleic acids from patient samples using advanced technologies and bioinformatic algorithms, ultimately leading to personalized treatments, increased drug efficacy, reduced side-effects, and improved patient outcomes.

The latest funding round was a Private Equity Round investment on 26 April 2023, with TA Associates as the investor. Diatech Pharmacogenetics operates within the Biotechnology, Health Care, and Pharmaceutical industries and continues to drive innovation in the field of precision medicine.